Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy Non-antigenic-amine-derived-polymers-and-polymer-conjugates

 Methods of treating Parkinson's disease using melanin
OF THE INVENTION One aspect of the present invention relates to the treatment of a mammal having a ...


 Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds
OF THE INVENTION The present invention thus provides as a novel compound the R(+)-enantiomer of N-...


 L-DOPA ethyl ester to treat Parkinson's disease
OF THE INVENTION This invention provides a composition which comprises a pharmaceutically ...


 Episomal vector systems and related methods
The present invention provides papilloma virus episomal vector systems and methods for papilloma ...


 Method for treating Parkinson's disease employing an ATP-sensitive potassium channel blocker
What is claimed is: 1. A method for treating Parkinson's disease, which comprises administering ...


 Method of treatment of parkinson's disease
We claim: 1. A method of treatment of Parkinson's disease in a patient in need of such treatment, ...


 4-aminoethoxy indolone derivatives
What is claimed is: 1. A compound of the formula I: ##STR5## in which: Y is hydrogen, halogen or ...


 Genetically engineered cells that produce produce L. Dopa
In one aspect, the present invention provides a process of increasing the production of dopamine in ...


 C. elegans deletion mutants
What is claimed is: 1. A nematode having null mutations in hop-1 and sel-12, said nematode having a ...


 Feline hepatocyte growth factor
The invention claimed is: 1. An isolated DNA or RNA encoding a protein having an amino acid ...


 Non-antigenic amine derived polymers and polymer conjugates

Details
Inventors: Greenwald, Richard B.; Martinez, Anthony; Pendri, Annapurna;
Assignee: Enzon, Inc. (Piscataway, NJ)
Primary Examiner: Harrison; Robert H.
Assistant Examiner:
Attorney, Agent or Firm: Roberts & Mercanti, LLP

Substantially non-antigenic polymers containing pI and/or pH optimum modulating moieties are disclosed. The polymers are useful as intermediates for synthesis of amine-based polymers and in the formation of activated polymers for conjugation with nucleophiles. Conjugates and methods of preparation and treatment with the conjugates are also disclosed.

DETAILED DESCRIPTION In one aspect of the invention, there are provided amine-based polymer intermediates having the formula: R--B (I) wherein (R) is a water-soluble, substantially non-antigenic polymer residue and (B) is preferably a secondary amine or a tertiary amine.
Suitable secondary amines are of the formula: --NH(CH.
sub.
2).
sub.
n X (II) wherein: (n) is an integer from 1-12, inclusive; and X is selected from the group consisting of H; OH; CO.
sub.
2 R.
sub.
1, where R.
sub.
1 is H or a C.
sub.
1-6 alkyl; halogen, atyl moieties and heteroaromatic moieties.
Suitable tertiary amines can be selected from: ##STR1## wherein (m) is an integer from 0-12, inclusive; (X) is selected from the group consisting of H, OH, CO.
sub.
2 R.
sub.
1, where R.
sub.
1 is H or a C.
sub.
1-6 alkyl, halogen, aryl moieties and heteroaromatic moieties; (Y) is N or CH; and (Z) is a C.
sub.
1-6 alkyl.
The polymer is preferably a poly(alkylene oxide) residue such as a poly(ethylene glycol) having a molecular weight between about 200 and about 100,000.
In addition, the polymer is preferably capped with a C.
sub.
1-4 alkyl group on the end opposite (i.
e.
distal to) the B moiety.
In another aspect of the invention, there are provided substantially non-antigenic polymers of the formula: R--B'--W--L (VII) wherein (R) is as defined above; (B') is NY, where Y is H i.
e.
, a secondary amine or a C.
sub.
1-6 alkyl or cycloalky i.
e.
, a tertiary amine, (W) is a spacer group, such as a C.
sub.
1-6 alkyl and (L) is a functional group capable of bonding with nucleophdies.
Other aspects of the invention include polymer conjugates containing biologically-active materials, described as nucleophiles herein as well as methods of conjugate preparation.
In these aspects of the invention, the conjugates are of the formula: [R--B'--W--L.
sup.
1 ].
sub.
z -(nucleophile) wherein: (R), (B') and (W) are as described above; (L.
sup.
1) represents a covalent linkage between (R--B'--W) and a nucleophile; and (z) represents the number of polymers attached to the nucleophile



Related patents
  Biodegradable high molecular weight polymeric linkers and their conjugates
The present invention includes compounds of the formula: (D).sub.n --M--(R.sub.1).sub.m (I) wherein (m) and (n) independently selected positive integers, preferably from ...
  Modified polypeptides with high activity and reduced allergenicity
OF THE INVENTION The modified polypeptide of the present invention is represented by the formula: A-B.sub.n containing, as essential components, a enzyme, A, and a ...
  Poly(ethylene glycol) derivatives with proximal reactive groups
OF THE INVENTION The terms "group," "functional group," "moiety," "active moiety," "reactive site," reactive group" and "reactive moiety" are used in the art and herein ...
  Devices for cloaking transplanted cells
A variety of devices can be used to contain or cloak a source of a therapeutic substance, often cells, which source provides the substance to a host or recipient subject....
  Terminally-branched polymeric linkers and polymeric conjugates containing the same
In one aspect of the invention, compounds of Formula (I) are provided: ##STR6## wherein: J is ##STR7## E.sub.1-4 are independently selected from the group consisting of ...
  Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising rectally administering to a patient a ...
  Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising a therapeutically effective dosage amount of an ...
  Rectally absorbable form of L-dopa
What is claimed is: 1. A pharmaceutical composition for enhancing rectal absorption of L-dopa by administering a formulation comprising a therapeutically effective ...
  Method to treat Parkinsons disease
I claim: 1. The method of treatment of Parkinson's disease and related neurological syndromes which consists of administering by the oral or sublingual route to a ...
  Method of using cytoprotective alcohols to treat neural disease and neural injury
The present invention is grounded in the surprising discovery that hexacosanol and analogues and homologs thereof, including saturated and unsaturated straight chain ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved